Drugs

Daily Pill Could Help Optimize Insulin Use

New studies have investigated a once-daily pill that can optimize insulin therapy and reduce HbA1c among adults with type 1 diabetes. The pill, a novel liver-selective glucokinase activator, also known as TTP399, showed superior A1c reduction compared to placebo. Read more

How SGLT2 Inhibitors Affect Risk of Death

A recent study that aimed to review and assess all the current evidence regarding SGLT2 inhibitors and their impact on death from all causes in diabetes patients found that overall, this class of diabetes drug was associated with a reduction in all-cause mortality. Read more

Effect of Empagliflozin on Kidney Disease

Empagliflozin (sold under the brand name Jardiance) may reduce major adverse kidney events in some type 2 diabetes patients better than other medications, researchers say. The study used U.S. Department of Veterans Affairs (VA) data to assess the effectiveness of empagliflozin versus other antihyperglycemic drugs. Read more

Immunosuppressive Medication Shows Potential for Type 1 Treatment

Golimumab is a human antibody that is used as an immunosuppressive drug (brand name Simponi) and is approved for the treatment of several autoimmune conditions, including ulcerative colitis. Researchers investigated whether golimumab could preserve beta-cell function in young people newly diagnosed with type 1 diabetes. Read more

Could Diabetes Drug Sitagliptin Help Treat COVID-19?

Some research has suggested that inhibiting the protein DPP-4, which is produced by the human body, could provide benefit to patients infected with COVID-19. Sitagliptin is a diabetes drug in the DPP-4 inhibitor class that has also shown anti-inflammatory and immunoregulatory effects. Researchers investigated whether sitagliptin could help treat hospitalized COVID patients with type 2 […]

Assessing Metformin in the Diabetes Landscape

Metformin is the standard first medication treatment of choice for people newly diagnosed with type 2 diabetes. A group of researchers decided to examine whether metformin, which this year celebrates its 63rd anniversary as a type 2 diabetes treatment, continues to earn its spot as a key member of the diabetes medication “All-Star Team.” Read more

The Consequences of Polypharmacy in the Elderly

Many older patients with type 2 diabetes deal with polypharmacy — taking multiple medications for their diabetes and other conditions. Polypharmacy can be burdensome in various ways, including multiple side effects of the various medications. Researchers investigated whether the use of polypharmacy put elderly patients at increased risk for hospitalization, falls, and death from all […]

Sotagliflozin and Chronic Kidney Disease

A recent phase 3 clinical trial on the diabetes drug sotagliflozin, an SGLT2 inhibitor, found it had favorable results for people living with severe renal impairment / chronic kidney disease.  Read more

How Do Metformin and Exercise Affect Glucose?

People who have prediabetes or type 2 diabetes are usually urged to make lifestyle modifications, including diet, exercise, and weight control as the first form of treatment; metformin is typically the first drug prescribed when lifestyle interventions are insufficient. A recent study examined how the interface of physical activity and metformin affects post-meal glucose in […]

Drug Combo Could Help Patients Who No Longer Respond to Metformin

Metformin is the first-line drug treatment for type 2 diabetes, but in some patients, the drug’s effectiveness can decline over time. A clinical trial has found that a combination of two newer diabetes drugs, exenatide and dapagliflozin, is effective in patients whose blood glucose levels did not respond to metformin. Read more

Can Semaglutide Add Years to Your Life?

The diabetes drugs known as the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class have demonstrated clear benefit for cardiovascular disease associated with diabetes. Researchers wanted to take a closer look at one GLP-1 RA medication, semaglutide, and determine how many years can be added to a patient’s life with this drug’s addition. Read more

Can DPP-4 Inhibitors Increase Pneumonia Risk?

Patients with diabetes have a higher risk for developing pneumonia, including viral pneumonia. Since the DPP-4 protein plays a role in infection for some coronaviruses, researchers wanted to study whether using DPP-4 inhibitor diabetes drugs could increase risk for pneumonia. Read more

Which Diabetes Drug Class is Better for the Heart?

Uncontrolled or poorly controlled type 2 diabetes is linked to many serious consequences, including death, heart failure, stroke, and myocardial infarction. A recent study compared the use of two antidiabetic medications, SGLT-2 inhibitors (such as Invokana and Jardiance) and GLP-1 receptor agonists (such as Bydureon and Farxiga), to see if one offered better cardiovascular protection. […]

Drugs Used to Treat HIV, Hepatitis May Also Prevent Type 2

A class of drugs called Nucleoside reverse-transcriptase inhibitors (NRTIs), which has long used to treat HIV and hepatitis B viral infections, appears to prevent the development of type 2 diabetes in a substantial number of patients who take these drugs, according to a new data analysis. Read more

Dulaglutide Can Help Protect the Heart

Cardiovascular issues in people with type 2 diabetes are approximately twice as common as in individuals without type 2. The results of a large trial, REWIND, suggest that dulaglutide (also called Trulicity) has cardioprotective properties.  Read more

Mixed Effects of Combining 2 Drugs, Canagliflozin & Liraglutide

Researchers examining the effects of combining the diabetes drugs canagliflozin, an SGLT2i, plus liraglutide, a GLP-1 RA, found that the combo was not much more effective than for lowering HBA1c than liraglutide alone, but the combo did have some weight loss benefits. Read more

How Safe is Dapagliflozin in the Elderly?

The SGLT-2 inhibitors are a relatively new treatment for type 2 diabetes, and the authors of this study felt their use had not yet been adequately studied in the elderly. They examined the effect of one SGLT-2 inhibitor, dapagliflozin (brand name Farxiga) to assess its effects on blood glucose control and kidney health in senior […]

Add an SGLT-2 Sooner Rather Than Later

For most people diagnosed with type 2 diabetes, the first treatments to be prescribed (aside from lifestyle changes like diet and exercise) are metformin or sulfonylureas. If these do not achieve the desired result, doctors may add additional medications. New research says that there is reason to add the SGLT-2 inhibitor early, as the second […]

Sitagliptin Shows Benefit in Diabetes Patients with COVID-19

The type 2 diabetes drug sitagliptin improves survival in patients with diabetes who have been hospitalized with COVID-19, according to Italian researchers. Patients who were given sitagliptin in addition to insulin had a mortality rate of 18 percent, versus 37 percent in similar patients who received insulin alone. Read more

Diabetes Drug Jardiance Shows Heart Failure Benefits

Jardiance (empagliflozin) has been studied for its use in people with heart failure. A study has found it shows effectiveness in patients with reduced ejection fraction (HFrEF). In heart failure with reduced ejection fraction, the heart muscle does not contract efficiently, and a smaller percentage of blood is pumped out of the heart than usual. […]